Abeona buys EoE drug ABO-801 for $20M in stock, raises $30M PIPE
What's the deal? Abeona TherapeuticsDealroom has a profile for this one. Try Dealroom → has acquired APT-1011, now renamed ABO-801, a Phase 3-ready eosinophilic esophagitis (EoE) drug candidate, from Ellodi PharmaceuticalsDealroom has a profile for this one. Try Dealroom →. The Cleveland-based company agreed to pay $20 million in common stock, with no upfront cash, and separately signed a securities purchase agreement for a $30 million private placement.
What's the asset? ABO-801 is a once-daily, orally disintegrating tablet of fluticasone propionate that delivers topical corticosteroid directly to the esophagus while limiting systemic exposure. It carries US Food and Drug Administration Orphan Drug and Fast Track designations for EoE, a chronic inflammatory disease affecting roughly 360,000 diagnosed patients in the US.
The terms: Beyond the stock at closing, Ellodi is eligible for $30 million on FDA approval and up to $30 million more on sales milestones, plus tiered royalties on net sales.
What's the endgame? Abeona wants to become a "diversified commercial-stage company," chief executive officer Vish Seshadri said, adding a late-stage orphan-drug asset alongside its approved skin therapy ZEVASKYN. The company plans to start a new Phase 3 study in mid-2027, with topline results expected by the end of 2028.
What could go wrong? ABO-801 comes with a mixed record: neither of its two completed Phase 3 studies met the prespecified co-primary patient-reported symptom endpoint, though both showed statistically significant gains on several endoscopic measures. The drug has been tested across more than 360 Phase 3 patients, and those results now inform the planned trial design.
Why now? Abeona had $134.9 million in cash and short-term investments as of September 30, 2026, and posted Q3 net ZEVASKYN revenue of $13.5 million, up 18% sequentially. The no-cash structure and fresh PIPE let it expand the pipeline without draining that balance.
The signal: The deal shows a newly commercial biotech using its stock, rather than cash, to buy a de-risked late-stage asset and build a second revenue line. For sellers like Ellodi — backed by investors including TPG — milestone-and-royalty structures offer a path to value when a programme needs another trial to reach the market.
Read more: pr.lakeoconeebreeze.net, Business Insider
Image credit: Generated with Gemini
